Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MIF | P14174 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CD74 | P04233 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490178 | 1.00 | DDB1 (0.46) | DDB1CRBNKCNJ1IDO1KMT2A | |
| SCHEMBL1161574 | 0.87 | PKM (0.49) | KMT2AMAPK1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL8218368 | 0.85 | MIF (0.53) | DDB1CRBNKCNJ1IDO1KMT2A | |
| SCHEMBL8252252 | 0.83 | CA12 (0.46) | DDB1CRBNKCNJ1IDO1KMT2A | |
| SCHEMBL30630697 | 0.83 | CA12 (0.46) | DDB1CRBNKCNJ1IDO1KMT2A | |
| SCHEMBL14470060 | 0.83 | DDB1 (0.40) | DDB1CRBNKCNJ1IDO1KMT2A | |
| SCHEMBL8139447 | 0.82 | DDB1 (0.42) | DDB1CRBNKCNJ1IDO1KMT2A | |
| SCHEMBL8190046 | 0.81 | DDB1 (0.41) | DDB1CRBNKCNJ1IDO1KMT2A | |
| SCHEMBL8184720 | 0.80 | IDH1 (0.43) | DDB1CRBNKCNJ1IDO1KMT2A | |
| SCHEMBL16413549 | 0.80 | ALDH1A1 (0.54) | DDB1CRBNIDO1KMT2AMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
| US-8569282-B2 | Carboxamide compounds and their use | CYTOPATHFINDER, INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| WO-2011012622-A1 | BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012622-A1 | BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| WO-2009076404-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR | EPIX DELAWARE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | DDB1 2908/4885CRBN 2475/4885KCNJ1 4674/4885 |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | DDB1 3105/4885CRBN 2525/4885KCNJ1 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.